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Abstract: Pancreatic Ductal Adenocarcinoma (PDA) is an aggressive malignancy with a very
poor outcome. Although chemotherapy (CT) treatment has poor efficacy, it can enhance tumor
immunogenicity. Tumor-Associated Antigens (TAA) are self-proteins that are overexpressed in tumors
that may induce antibody production and can be PDA theranostic targets. However, the prognostic
value of TAA-antibody association as Circulating Immune Complexes (CIC) has not yet been
elucidated, mainly due to the lack of techniques that lead to their identification. In this study,
we show a novel method to separate IgG, IgM, and IgA CIC from sera to use them as prognostic
biomarkers of CT response. The PDA Immune-Complexome (IC) was identified using a LTQ-Orbitrap
mass spectrometer followed by computational analysis. The analysis of the IC of 37 PDA patients
before and after CT revealed differential associated antigens (DAA) for each immunoglobulin class.
Our method identified different PDA-specific CIC in patients that were associated with poor prognosis
patients. Finally, CIC levels were significantly modified by CT suggesting that they can be used as
effective prognostic biomarkers to follow CT response in PDA patients.
Keywords: proteomics; pancreatic cancer; chemotherapy; immune complexes; biomarkers; TAA;
computational analysis
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1. Introduction
The role of the immune system in cancer has been extensively studied, due to its critical role
in counteracting tumor development. The field of cancer immunology has elicited growing interest
because of the success obtained in many cancers [1]. Even in tumors defined as immunologically “cold“
(i.e., with a low infiltrate of T cells), such as pancreatic cancer, the possibility to exploit the immune
system to identify biomarkers or immunological targets has been demonstrated [2–7].
Immune complexes (IC) are those formed between the antibody and its antigen [8].
The self- or non-self-antigens are bound to immunoglobulins by non-covalent interactions.
Circulating Immune Complexes (CIC) are present in healthy subjects and cooperate in the immune
response [9]. In healthy subjects, IC are removed from the bloodstream, while, in pathological
conditions, CIC can accumulate in the bloodstream or in different tissues, especially in the kidneys,
inducing glomerulonephritis [8]. Pathological CIC were discovered as biomarkers of Raynaud’s
syndrome [8]. Indeed, the accumulation of CIC could provide a novel source of biomarkers for the diagnosis
and the follow-up of a pathological condition. The use of CIC as disease biomarkers was specifically
studied for autoimmune diseases, such as systemic lupus erythematosus [9,10] and rheumatoid arthritis [8],
but it was also observed in other pathologies, including infectious diseases and acquired thrombotic
thrombocytopenic purpura [8,11,12]. Of note, the level of CIC increases in the presence of several
malignancies. In the 1970s, CIC were found in melanoma, osteogenic sarcoma, lymphoma and carcinomas
of the colon, lungs, breast, prostate, pancreas, stomach, esophagus, and uterine cervix [13,14]. However,
a systematic analysis of CIC was provided only in 2013 in uveitis, using pull-down assays to separate
IgG-IC [15]. One of the main reasons for this delay was the lack of a specific assay to detect and quantify
CIC, which led to the missing identification of specific biomarkers in malignancies until now.
With the advent of high-throughput technologies, such as mass spectrometry, the study
of CIC has become more accurate. Thus, several techniques have been used to study IC,
including ultracentrifugation, ELISA, gel filtration, ultrafiltration, precipitation with polyethylene
glycol, assays based on interactions with purified complement portions, quantitative dot-blot assay,
and Raji cell radioimmunoassay. Furthermore, CIC were also studied through assays that measured
their effects on other cells such as platelet aggregation tests, inhibition of antibody-dependent
cytotoxicity assays, tests for the release of enzymes from eosinophils and mast cells, and macrophages
inhibition assays [8–10,13]. However, most of these techniques allow the investigation of the presence
of CIC bounded with already known antigens, without identifying novel CIC-associated antigens.
Immunoglobulin (Ig) G is the main Ig class in human blood, and it represents about 70% of
the total Ig pool. For this reason, in studies performed on the humoral response, attention has
mainly been focused on IgG class response, including our previous studies on antibody response
in PDA patients [2,4,16]. However, the role of other Ig classes in cancer could also be relevant.
Indeed, it was demonstrated that IgM and IgG antibodies were bound to allogeneic tumor cells [17].
Conversely, a subpopulation of IgA-secreting B cells that suppresses the activation of CD8+ T cells in
prostate cancer, after oxaliplatin treatment, was identified [18]. Moreover, several studies identified
IgM CIC containing squamous cell carcinoma antigen or carcinoembryonic antigen, which have
diagnostic value in hepatocellular carcinoma and colorectal cancer, respectively [19,20].
Demonstrating the association between CIC levels of cofilin-1 in sera with cancer progression
and poor prognosis has highlighted the importance of IC in PDA [21]. It has been well
established that chemotherapy (CT) influences the humoral and cellular immune responses to
the tumors [22], and, therefore, identifying CIC that can predict responses or resistance to CT
could allow the maximization of the efficacy of treatments and could avoid useless toxic effects
in non-responding patients [23].
Here, we propose a systematic analysis of IgG, IgM, and IgA CIC in PDA. For the first time,
we have demonstrated that, in PDA, identifying novel Tumor-Associated Antigens (TAA) associated
with different classes of Ig patients treated with CT can provide new prognostic markers.
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2. Results
We performed a systematic analysis of the PDA IC. The CIC-containing different
Ig subclasses were sequentially separated and then analyzed by high resolution mass
spectrometry (further details in Section 4). Sera from PDA before and after gemcitabine-based CT
(namely BCT and ACT, respectively) were collected and analyzed. The IC bound to IgG, IgM, and IgA
classes obtained from 37 PDA patients were subdivided into five groups characterized by different
disease prognosis. Group one consisted of patients with the best prognosis, while in group five were
patients with the worst prognosis (Supplementary Table S1A and Figure 1A). In each group, sera were
pooled and the pooled IC content was analyzed using an LTQ-Orbitrap mass spectrometer (Figure 1A).
For detailed information, see the Materials and Methods section). In order to identify CIC markers
that could be informative for PDA prognosis and CT response, we analyzed the pooled sera of each
BCT and ACT group. In this analysis, we identified 3547 proteins bound to IgG, 1043 proteins bound
to IgM, and 1143 proteins bound to IgA before and after CT (Supplementary Table S1B–D). For each
class of immunoglobulins, we performed a three-step computational analysis. Firstly, to investigate
the effect of CT on the CIC content, the presence of each antigen before and after CT in each group was
analyzed. Then, the different levels of CIC measured in the five BCT and ACT groups were analyzed
to identify possible trends (i.e., a CIC that is found to increase or decrease progressively from group
one to group five). Finally, the ACT/BCT ratio for each CIC in each group of patients was considered.
2.1. Analysis of IgG-Circulating Immune Complexes
The analysis of IgG-bound proteins BCT and ACT revealed that only
the TTR (thyroid hormone-binding protein) CIC was significantly down-modulated by
gemcitabine treatment (Figure 1B, p = 9.64 × 104, Table 1 and Supplementary Table S2A).
Considering BCT and ACT results separately, the analysis of different CIC levels in the five cohorts
showed a statistically significant trend for IGKV6D-21 (Immunoglobulin kappa variable 6D-21)
and IGLV7-46 (Immunoglobulin lambda variable 7-46) CIC in BCT data (Table 2). Conversely, IgG CIC
of APOC2 (Apolipoprotein C-II), C4B (Complement C4-B), and S100A9 (Protein S100-A9) increased
significantly from group one to group five in ACT data (p = 0.0274 and p = 0.043, respectively) (Table 3).
Interestingly, results from the trend analysis demonstrated that IGLV7-46 (BCT) and S100A9 (ACT)
showed the most significant trend (p = 0.027) as they were highly abundant in the low survival
patient group and absent in the high survival patient blood (Figure 1C, Supplementary Table S3A).
Trend analysis of CIC level BCT w.r.t. ACT (ACT/BCT ratio) in the five groups revealed 79
differentially recognized proteins (Supplementary Table S4A and Table S5A), with IGHV4-34
(immunoglobulin heavy variable 4-34) displaying a progressively increasing abundant trend
(ratio ACT/BCT: 1, 0.57, 0.07, 60.2, and 119.3 for groups 1, 2, 3, 4, and 5, respectively).
2.2. Analysis of IgM Circulating Immune Complexes
The analysis of IgM-bound proteins BCT and ACT revealed the statistically significant variation of
eight different protein levels, namely ADIPOQ (adiponectin), CDH5 (Cadherin-5), FCGBP (IgGFc-binding
protein), SERPINA3 (alpha-1-antichymotrypsin), NEO1 (Neogenin) and SERPIND1 (Heparin cofactor 2),
which were increased ACT, and HP (Haptoglobin) and KRT16 (Keratin, type I cytoskeletal 16),
which were decreased ACT (Figure 1D, Table 1 and Supplementary Table S2B). Analyzing the IgM
CIC levels in the five cohorts, considering BCT and ACT separately, revealed that seven proteins
were significantly modulated w.r.t. patient survival: AOC3 (membrane primary amine oxidase),
APCS (serum amyloid P-component), APOB (apolipoprotein B-100) and IGLV3-25 (immunoglobulin
lambda variable 3-25) in the BCT data (Table 2). GAPDH (glyceraldehyde-3-phosphate dehydrogenase),
IGLV1-47 (immunoglobulin lambda variable 1-47), and OLFM2 (noelin-2) were increased significantly
in the ACT data (Table 3). CIC containing AOC3, APOB, IGLV3-25, IGLV1-47, and OLFM2
decreased from group 1 to group 5 while those with APCS and GAPDH increased in
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abundance (Figure 1E, Tables 2 and 3 and Supplementary Table S3B). Comparing the ACT/BCT
ratios between the five groups, 30 proteins were identified as being significantly modulated
(Supplementary Tables S4B and S5B). Of such proteins, ADIPOQ, AOC3, and SERPINA1 showed
the most significant trends (p-value < 0.0001), and their level progressively increased from group 1
to group 5 (Supplementary Table S4B).
Table 1. List of differentially recognized Circulating Immune Complexes.
Gene Name Ig Subtype Variation Following Chemotherapy
TTR IgG decreased
ADIPOQ IgM increased
CDH5 IgM increased
FCGBP IgM increased
HP IgM decreased
KRT16 IgM decreased
NEO1 IgM increased
SERPINA3 IgM increased
SERPIND1 IgM increased
ABCA13 IgA increased
ECM1 IgA decreased
IGHG3 IgA decreased
IGKV3-20 IgA decreased
IGLV1-40 IgA increased
IGLV7-43 IgA decreased
XIRP2 IgA increased
Table 2. List of significant Circulating Immune Complexes trends before chemotherapy.
Gene Name Ig Subtype Trend (from Group 1 to 5)
IGKV6D-21 IgG increasing
IGLV7-46 IgG increasing
AOC3 IgM decreasing
APCS IgM increasing
APOB IgM decreasing
IGLV3-25 IgM decreasing
APOL1 IgA increasing
IGHV3OR16-9 IgA increasing
MMRN2 IgA increasing
SERPINC1 IgA decreasing
SERPIND1 IgA increasing
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Figure 1. Analyses of IgG, IgM, and IgA immuno-complexes upon chemotherapy (CT) in sera of PDA
patients. (A) scheme of the experimental design of the immune-complexome proteomic analysis using
pulled sera from PDA patients collected before and after CT (BCT and ACT). Samples were divided
into pools based on the months of disease-free survival; (B) Bar plot representing the circulating level
of TTR (IgG differential associated antigen (DAA)) BCT and ACT; (C) bar plots representing the most
significant trends of IgG Circulating Immune Complexes (CIC) considering BCT and ACT results
separately. Both IgG-IGLV7-46 (left panel) and IgG-S100A9 (right panel) increased from good to bad
prognosis in the five groups; (D) heat map showing IgM DAA in the five groups of patients; (E) bar
plots representing the most significant trends of IgM CIC considering BCT and ACT results separately.
Both IgM-APCS (left panel) and IgM-GAPDH (right panel) increased from good to bad prognosis in
the five groups; (F) heat map showing IgA DAA in the five groups of patients; (G) bar plots representing
the most significant trends of IgA CIC considering BCT and ACT results separately. IgA-SERPINC1 (left
panel) decreased from good to bad prognosis and IgA-PTGDS (right panel) increased from good to bad
prognosis in the five groups. All CIC are represented as number of Peptide-Spectrum Matches (PSM).
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Table 3. List of significant Circulating Immune Complexes trends after chemotherapy.
Gene Name Ig Subtype Trend (from Groups 1 to 5)
APOC2 IgG decreasing
C4B IgG decreasing
S100A9 IgG increasing
GAPDH IgM increasing
IGLV1-47 IgM decreasing
OLFM2 IgM decreasing
C9 IgA increasing
FREM2 IgA increasing
IGHD IgA increasing
KCNQ2 IgA increasing
PTGDS IgA increasing
2.3. Analysis of IgA Circulating Immune Complexes
The analysis of IgA-bound proteins BCT and ACT revealed the significant
modulation of seven proteins: ABCA13 (ATP Binding Cassette Subfamily A Member 13),
IGLV1-40 (Immunoglobulin Lambda Variable 1-40) and XIRP2 (Xin Actin Binding Repeat Containing 2)
which increased ACT and ECM1 (Extracellular Matrix Protein 1), IGHG3 (Immunoglobulin Heavy
Constant Gamma 3), IGKV3-20 (Immunoglobulin Kappa Variable 3-20) and IGLV7-43 (Immunoglobulin
Lambda Variable 7-43) which decreased ACT (Figure 1F, Table 3 and Supplementary Table
S2C). Considering results BCT and ACT separately, the analysis of CIC levels in the five
cohorts showed a statistically significant trend for 10 proteins: APOL1 (apolipoprotein L1),
IGHV3OR16-9 (immunoglobulin heavy variable 3/OR16-9), MMRN2 (multimerin-2), SERPINC1
(antithrombin-III), and SERPIND1 (heparin cofactor 2) in the BCT condition (Table 2),
while C9 (complement component C9), FREM2 (FRAS1-related extracellular matrix protein 2),
IGHD (immunoglobulin heavy constant delta), KCNQ2 (potassium voltage-gated channel subfamily
KQT member 2), and PTGDS (prostaglandin-H2 D-isomerase) were detected in the ACT condition
(Table 3 and Supplementary Table S3C). Interestingly, all these CIC, increased from group 1 to
group 5, except for SERPINC1, which decreased in abundance (Figure 1G and Table 2). In ACT
CIC containing PTGDS progressively decreased from group 1 to group 5 (Figure 1G and Table 3).
Comparing the modulation of CT in the trends of CIC BCT and ACT in the five groups, 47 proteins were
identified as statistically significantly related to patient survival (Supplementary Tables S4C and S5C).
PTGDS, KCNQ2, PDE4A, MAN1C1, IGHV3-23, OBSNC, and BRSK2 were characterized as having
the most significant trend that increased from group 1 to group 5 while MRPS26 decreased significantly
from group 1 to group 5.
2.4. Enrichment Analysis of IgA, IgM and IgG CIC
To predict candidate biological processes and signaling pathways that are enriched in the set of
antigens bound to the CIC, we performed an enrichment analysis of combined IgA, IgM, and IgG DAA.
This revealed different enriched processes and phenotypes including “PDA genesis“, “type II diabetes
mellitus onset“, and “extracellular vesicles“ (Supplementary Table S6). PDA genesis, insulin secretion,
and diabetes pathways confirm the accuracy of our analysis.
3. Discussion
The relationship between CIC and tumors has been known for many years, but a full and complete
comprehension of the role of CIC in cancer is still lacking. The observation of elevated levels of
CIC in the presence of malignancies dates back to the 1970s [13,14]. However, the study of CIC
remained a challenge until the development of mass spectrometry. In fact, in the past, CIC were
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studied with methods that separated them only roughly, and assumed for the analysis the prior
knowledge of the antigen under study, thus not allowing the discovery of new antigens [8–10,13].
Instead, the combination of a proper CIC separation and mass spectrometry as presented here leads to
the identification of the proteins involved in the disease, opening new perspectives to investigate
the role of these CIC in cancer.
In this article, we have proposed a novel approach to investigate CIC that has led us to identifying
important TAA suitable to be follow-up biomarkers. The analysis was performed on the sera of
patients with PDA before and after gemcitabine-based CT. Currently, we are recruiting a large number
of PDA patients in a multi-center clinical study in order to confirm and validate the prognostic role of
CIC-bound TAA identified in this study.
In contrast to previously used methods that allowed the separation of all immunoglobulin
repertoire (ultracentrifugation, gel filtration, ultrafiltration, precipitation with polyethylene glycol) [8]
or the enrichment of CIC containing IgG only [15,16], we presented a systematic analysis of CIC
containing IgG, IgM, and IgA isotypes that we define as the “immune-complexome“. This represents
a technical and conceptual improvement that was found of particular interest. In fact, we demonstrated
that the proteins bound to different classes of immunoglobulins, and their changes in relation to
CT, defined different patterns of response to CT, underlying the need to consider them separately.
Of interest, proteins bounded to immunoglobulins also showed marked differences with respect to
serum-free circulating proteins [24].
The most interesting outcome of this study is that the clinically relevant CIC trends were from
the IgM fraction. It is known that IgM CIC are more frequent w.r.t. IgG ones because the clearance
of IgG CIC is maintained by (i) the activation of complement by a classical pathway and (ii) the Fc
gamma receptors (FcγR) system which is present on the surface of different cells of the immune system.
This second modality of CIC clearance is not employed for IgM CIC. For this reason, it is possible that
proteins bound to IgM reflect the earliest humoral response to PDA after CT. Of note, the IgG fraction
is not the most important class associated with protein markers in our analysis; although sera IgG
were the most present quantitatively, they showed less informative cues when the purpose was to
identify of IgG-associated biomarkers following CT treatment.
Enrichment analysis strongly reinforced the robustness of our study, highlighting many
processes related to pancreatic cancer (PDA genesis, type II diabetes mellitus onset, and
insulin secretion). Notably, the enrichment in protein localized in the extracellular vesicle
was particularly interesting, since a significant enrichment of exosome in the Ig-bound
fraction was demonstrated in the sera of PDA patients compared to healthy subjects [16].
Moreover, several identified antigens have been previously correlated to PDA, although not in
association with immunoglobulins, namely TTR (thyroid hormone-binding protein) and S100A9
(protein S100-A9) were found in IgG CIC [25,26], ADIPOQ (adiponectin), CDH5 (cadherin-5),
FCGBP (IgGFc-binding protein), HP (haptoglobin), GAPDH (glyceraldehyde-3-phosphate
dehydrogenase), and SERPINA1 (serine proteinase inhibitor A1) in IgM CIC [24,27–29],
BRSK2 (BR Serine/Threonine-Protein Kinase 2) in IgA CIC.
TTR and HP bound to fucose have been already proposed as a biomarkers of PDA [30,31]; CDH5 in
pancreatic neuroendocrine tumors developed in Von Hippel–Lindau disease patients [32] and FCGBP
in mucinous cysts in the pancreas [33] and PDA [34]. S100A9 is a calcium- and zinc-binding protein
with a key function in regulating inflammation and immune responses, and has been previously
associated with PDA inflammation status, invasiveness, and metastasis [25,35]; in our experimental
setting, S100A9 levels increased in case of worst prognosis. ADIPOQ levels were correlated to
various kinds of cancers [36], but its role has not been well understood, yet. Indeed, even though
the preponderance of evidence suggests an inverse correlation of serum ADIPOQ levels with cancer,
other studies correlated the increase of ADIPOQ levels with cancer progression [36]. In the case
of PDA, the scenario is particularly disputable. Adiponectin inhibits PDA proliferation of Pan02
cells both in vitro and in vivo when cells were transplanted in a murine model, by induction of
Cancers 2020, 12, 746 8 of 14
caspase-3 and caspase-7 and apoptosis [37]. Conversely, in the same year, it was showed that
ADIPOQ inhibited apoptosis of pancreatic cancer cells in the same murine model via activation of
AMPK-Sirt1-PGC1α signaling [27]. In human studies, the situation is controversial; adiponectin in
pancreatic cancer patients has been separately observed to be elevated [38–40], decreased [41,42],
and unchanged [43,44]. A possible explanation of these conflicting results could be that, as shown in
this study, ADIPOQ is not important by itself, but the ADIPOQ bound to IgM. In fact, we showed
a very interesting trend, with IgM-ADIPOQ levels significantly increasing with worse prognoses.
GAPDH, which we observed to increase in being bound to IgM from the group one to the group
five ACT, has already been correlated to PDA with a worse prognosis [24]. SERPINA1 is up-regulated
in PDA tissue and serum [45] and has been proposed as a prognostic factor in pancreatic cancer [46].
BRSK2, which we saw to increase from group one to group five, was demonstrated to provide a survival
advantage to PDA cells [47].
Other identified antigens have been correlated to other types of cancer, namely
ABCA13 in ovarian cancer [48], XIRP2 in gastric cancer [49], and APOC2 expression
in Non-Small Cell Lung Cancer [50]. Typical serum proteins were among the identified ones,
despite the immune depletion before the mass spectrometry analysis. We found complement
proteins, immunoglobulins, apolipoproteins, and inflammation proteins, some of which were
significantly modulated by CT, namely APOC2 (apolipoprotein C-II), C4B (complement C4-B),
IGLV7-46, IGHV4-34 (immunoglobulin heavy variable 4-34) in IgG CIC, APOB (apolipoprotein
B-100), IGLV3-25 (immunoglobulin lambda variable 3-25), IGLV1-47 (immunoglobulin lambda
variable 1-47) and SERPINA1 in IgM CIC, APOL1 (apolipoprotein L1), C9 (complement component
C9), IGHG3, IGKV3-20, IGLV1-40, IGLV7-43, IGHV3OR16-9 (immunoglobulin heavy variable
3/OR16-9), IGHD (immunoglobulin heavy constant delta), IGHV3-23, SERPINC1 (antithrombin-III)
and SERPIND1 (heparin cofactor 2) in IgA CIC. Concerning the role of CIC in cancer, very little
data are available. It has been reported that proteins bound to Ig could have a decoy function,
inhibiting antibody-dependent cytotoxicity [16]. This aspect could be relevant to explain the increase
of the majority of the identified CIC after CT in parallel with prognosis getting worst; however, it is
certainly not the only role. It is likely that CIC binding could enhance the immune response against
a protein, but it could also sequester a protein rendering it ineffective. Depending on the role of
the antigen, this behavior could lead to a good or bad prognosis.
4. Materials and Methods
4.1. Patients
From 2006 to 2012, 37 patients with PDA, enrolled in ENOAPA project (https://www.
epiclin.it/enoapa), provided serum samples. The protocol was approved by the local
research ethical committee (Azienda Ospedaliera Città della Salute e della Scienza di Torino, Turin)
ethical code #0114454, November 23th, 2016.) and was performed according to the Helsinki
Declaration principles. All participants in the protocol signed a declaration of informed
consent. No patients were subjected to surgery and all were treated with gemcitabine-based
CT (gemcitabine with oxaliplatin or alone). Serum samples were isolated from venous blood
before and after CT and stored at −80 ◦C until use. Patients’ characteristics are listed in
Supplementary Table S1A. Patients were grouped into five groups on the basis of response to therapy
and survival, as indicated in Supplementary Table S2. An equal amount of serum from each patient in
each group was taken to reach a total volume of 300 µL.
4.2. IgG-IC Purification
HiTrap Protein G HP (1 mL) was used (GE HealthCare Life Sciences, Milan, Italy). The column
was operated with a peristaltic pump. All buffers were filtered before use. Serum was filtered with
a SPARTAN Syringe Filter, RC Filter Media, 13 mm diameter, 0.2 µm pore size (Whatman, Maidstone,
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UK) and then diluted at 1:3 in binding buffer (20 mM sodium phosphate, pH 7.0). The column
was washed with 5 mL of milliQ water and with 5 mL of binding buffer before sample application.
The sample was then passed through the column along with 9 mL of binding buffer, collecting
the “unbound fraction“ exiting from the column. IgG-IC were eluted from the column with 10 mL
of elution buffer (0.1 M glycine-HCl, pH 2.7) and collected in a tube containing 1 mL of neutralizing
buffer (1 M Tris-HCl, pH 9.0). All timing and volumes were optimized evaluating IgG presence by
Western blotting.
4.3. IgM-IC Purification
After the evaluation of their presence by Western blotting, IgM-IC were separated from the IgG
unbound fraction by HiTrap IgM purification HP 1 mL (GE HealthCare Life Sciences, Milan, Italy).
The column was operated with a peristaltic pump. The sample should have the same concentration of
ammonium sulfate as the binding buffer, so small amounts of solid ammonium sulfate were gradually
added to the sample until the final concentration was 1M, stirring slowly and continuously, to avoid
IgM precipitation. Samples were then filtered with SPARTAN Syringe Filter, RC Filter Media, 13 mm
diameter, 0.2 µm pore size (Whatman, Maidstone, UK). All buffers were filtered before use. Columns
were washed with 5 mL of binding buffer (20 mM sodium phosphate, 1 M ammonium, pH 7.5), 5 mL
of elution buffer (20 mM sodium phosphate, pH 7.5) and 5 mL of regeneration buffer (20 mM sodium
phosphate, pH 7.5 with 30% isopropanol) and then equilibrated with 5 mL of binding buffer. This was
then applied to the sample. The unbound fraction was washed out with 15 mL of binding buffer.
Elution was performed with 12 mL of elution buffer. Columns were then regenerated with regeneration
buffer and equilibrated with a binding buffer for the subsequent separation. All timings and volumes
were optimized evaluating IgM presence by Western blotting.
4.4. IgA-IC Separation
IgA-IC were present with the eluted IgM-IC fraction, as verified by Western blotting.
Indeed, starting from the elution containing IgM-IC, IgA-IC were separated by immunoprecipitation
with anti-human IgA (a chain specific)-agarose antibody (Sigma Aldrich, St. Louis, MO, USA).
After adding 1.9 mL of antibody, samples were incubated overnight at 4 ◦C on a rocking platform.
After three washes with PBS, IgA-IC were eluted with two elutions of 4 mL each of elution buffer
(0.1 M glycine-HCl, pH 2.7). Elutions were collected in a tube containing 0.8 mL of neutralizing buffer
(1 M Tris-HCl, pH 9.0).
4.5. LC-MS Analysis
All samples were concentrated to a volume of 500 µL using a 3KDa cut-off concentrator (Merck
Millipore,Burlington, MA, USA) at 4000 g for 60 min. They were then reduced with TCEP (35 µL in
each sample; incubation at 37 ◦C for 30 min) and alkylated with acrylamide (20 mg in each sample;
incubation at room temperature for 30 min in the dark). After buffer exchange with a solution
containing 20 mM Tris, 4 M urea, 3% isopropanol, pH 8.0, samples were subjected to reverse phase
separation as previously described [51]. Samples were then fractionated in protein level using
the Shimadzu HPLC system. The protein sample was loaded onto the RPGS reversed-phase column
(4.6 mm I.D. ×150 mm, 15 µm, 1000Å, Column Technology Inc., #RP5D46150) and desalted for 5 min
with 95% mobile-phase A (0.1% TFA in 95% H2O) at a flow rate of 3 mL/min. Proteins were eluted
from the column at a flow rate of 2.1 mL/min with a gradient elution including: (i) an increase
from 5 to 70% mobile phase B (0.1% TFA in 95% ACN) for more than 25 min, (ii) an increase
from 70% to 95% mobile phase B for 3 min, (iii) a wash step to hold at 95% mobile phase B for
2 min, (iv) a re-equilibration step at 95% mobile phase A for 5 min. The collected fractions were
pooled into 15 fractions. All fractions obtained in this way were lyophilized and proteins were
digested with trypsin. The analysis was performed using Orbitrap Elite. The tryptic peptides
were separated by reversed-phase chromatography using an EASYnano HPLC system (Thermo
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Scientific, Waltham, MA, USA) coupled online with a LTQ-Orbitrap ELITE mass spectrometer
(Thermo Scientific, Waltham, MA, USA). Mass spectrometer parameters were: spray voltage 2.5 kV,
capillary temperature 280 ◦C, Furier Transform (FT) resolution 60,000, FT target value 1 × 106, LTQ
target value 3 × 104, 1 FT microscan with 500 ms injection time, and 1 LTQ microscan with 10 ms
injection time. Mass spectra were acquired in a data-dependent mode with the m/z range of 400–2000.
The full mass spectrum (MS scan) was acquired by the FT, while the tandem mass spectrum (MS/MS
scan) was acquired by the LTQ with 35% normalized collision energy. Acquisition of each full mass
spectrum was followed by the acquisition of MS/MS spectra for the five most intense +2 or +3 ions
within a one second duty cycle. The minimum signal threshold (counts) for a precursor occurring
during a MS scan was set at 1000 for triggering an MS/MS scan.
The acquired LC-MS/MS data were processed by the Proteome Discoverer 1.4 (Thermo Scientific,
Waltham, MA, USA). Sequest HT was used as a search engine with input parameters including cysteine
(Cys) alkylated with acrylamide (71.03714@C) as a fixed modification and methionine (Met) oxidation
(15.99491@M) as a variable modification. Data were searched against the Uniprot Human database
2017 and further filtered with a False Discovery Rate (FDR) <=5%. Total mass spectra counts for each
protein were used as a measure of protein abundance.
4.6. Protein Identification and Bioinformatics Aanalysis
A new R computational pipeline to pre-process, normalize, and analyze obtained proteomic
data was applied. Our pipeline consisted of data characterization, individuation of differentially
associated antigen (DAA), trend analysis, and functional enrichment analysis. Using our approach,
we identified DAA and their trends upon CT. We also characterized the enriched biological processes
and phenotypes of the antigens identified.
4.7. Data Pre-Processing and Normalization
Spectra obtained from LTQ-Orbitrap were analyzed using SEQUEST software.
SEQUEST identified peptide sequences from tandem mass spectra. Peptides-Spectrum Matches (PSMs)
obtained from this analysis were filtered in order to take into consideration only IC with PSM > 1
or IC with PSM equal to 1 occurring in at least two groups. Filtered PSMs were normalized using
the quantile normalization method in R.
4.8. Differential Associated Antigens and Antigen Recognition Trends
Comparisons of IC abundance (before and after CT) were computed using
the DESeq2 R package [52]. Analysis of IC abundances’ trends among the five sample pools
was performed using MaSigPro R package [53] with default parameters.
4.9. Gene Set Enrichment Analysis
Gene list coding for identified proteins was retrieved using UniProt and BioDBnet and analyzed
using an Enrichr tool [54].
5. Conclusions
In conclusion, our method leads: i) to the identification of novel PDA specific CIC before and
after gemcitabine treatment, ii) to the characterization of CT effects on CIC levels. In this study,
we developed a new method that combines the capture of IC and mass spectrometry, allowing the
discovery that CIC-bound TAAs could be markers of CT response. Some of the identified candidate
CIC could be suitable for use as novel non-invasive prognostic markers.
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